Intraocular Implants for the Treatment of Autoimmune Uveitis
Source abstract
Abstract
Uveitis is the third leading cause of blindness in developed countries. Currently, the most widely used treatment of non-infectious uveitis is corticosteroids. Posterior uveitis and macular edema can be treated with intraocular injection of corticosteroids, however, this is problematic in chronic cases because of the need for repeat injections. Another option is systemic immunosuppressive therapies that have their own undesirable side effects. These systemic therapies result in a widespread suppression of the entire immune system, leaving the patient susceptible to infection. Therefore, an effective localized treatment option is preferred. With the recent advances in bioengineering, biodegradable polymers that allow for a slow sustained-release of a medication. These advances have culminated in drug delivery implants that are food and drug administration (FDA) approved for the treatment of non-infectious uveitis. In this review, we discuss the types of ocular implants available and some of the polymers used, implants used for the treatment of non-infectious uveitis, and bioengineered alternatives that are on the horizon.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ocular Diseases and Behçet’s Syndrome · Cytomegalovirus and herpesvirus research · Ocular Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Ophthalmology/Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, 608 Stanton L. Young Blvd, DMEI PA404, Oklahoma City, OK 73104, USA
References (100+)
Show source-provided references
1. Road to remission: A comprehensive review of therapy in uveitis10.1517/13543784.2011.617741 ↗
2. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease10.1016/j.survophthal.2011.05.003 ↗
3. Causes and frequency of blindness in patients with intraocular inflammatory disease10.1136/bjo.80.4.332 ↗
4. Epidemiology of uveitis. Incidence and prevalence in a small urban community10.1001/archopht.1962.00960030506014 ↗
5. Incidence and prevalence of uveitis in northern california; the northern california epidemiology of uveitis study10.1016/j.ophtha.2003.06.014 ↗
6. Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop10.1016/j.ajo.2005.03.057 ↗
7. Prete, M., Dammacco, R., Fatone, M.C., and Racanelli, V. (2015). Autoimmune uveitis: Clinical, pathogenetic, and therapeutic features. Clin. Exp. Med.10.1007/s10238-015-0345-6 ↗
8. Implants for drug delivery to the posterior segment of the eye: A focus on stimuli-responsive and tunable release systems10.1016/j.jconrel.2014.09.030 ↗
9. Barisani-Asenbauer, T., Maca, S.M., Mejdoubi, L., Emminger, W., Machold, K., and Auer, H. (2012). Uveitis—a rare disease often associated with systemic diseases and infections—a systematic review of 2619 patients. Orphanet J. Rare Dis., 7.10.1186/1750-1172-7-57 ↗
10. Risks of relapse in patients with acute anterior uveitis10.1136/bjo.2005.083725 ↗
11. Intraocular pressure effects of common topical steroids for post-cataract inflammation: Are they all the same?10.1007/s40123-013-0020-5 ↗
12. Glucocorticoid induction of the glaucoma gene myoc in human and monkey trabecular meshwork cells and tissues
13. Frequent methylprednisone pulse therapy is a risk factor for steroid cataracts in children10.1111/j.1442-200X.2008.02629.x ↗
14. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: Results of the multicenter uveitis steroid treatment trial10.1016/j.ophtha.2013.01.025 ↗
15. Side effects of corticosteroid therapy10.1097/00004836-200110000-00006 ↗
16. Methotrexate for ocular inflammatory diseases10.1016/j.ophtha.2009.04.020 ↗
17. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema10.1016/j.ophtha.2008.10.033 ↗
18. Corticosteroid-sparing agents: Conventional systemic immunosuppressants10.1159/000336185 ↗
19. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the italian registry10.3899/jrheum.120583 ↗
20. Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up10.1016/j.ajo.2007.08.018 ↗
21. Immunomodulatory therapy with tumour necrosis factor alpha inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: Long-term results10.1136/bjophthalmol-2013-303935 ↗
22. Ramanan, A.V., Dick, A.D., Benton, D., Compeyrot-Lacassagne, S., Dawoud, D., Hardwick, B., Hickey, H., Hughes, D., Jones, A., and Woo, P. (2014). A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (sycamore trial). Trials, 15.10.1186/1745-6215-15-14 ↗
23. Novel intraocular therapy in non-infectious uveitis of the posterior segment of the eye
24. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis10.1097/IAE.0b013e31828ac07d ↗
25. Biodegradable intraocular therapies for retinal disorders: Progress to date10.2165/11530970-000000000-00000 ↗
26. Attempts to map the structure and degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids10.1163/156856294X00581 ↗
27. Fabrication and characterization of permeable degradable poly(DL-lactide-co-glycolide) (PLGA) hollow fiber phase inversion membranes for use as nerve tract guidance channels10.1016/j.biomaterials.2006.02.036 ↗
28. Encapsulation, stabilization, and release of bsa-fitc from polyanhydride microspheres10.1016/j.jconrel.2004.08.006 ↗
29. Evaluation of tensile and absorption properties of polyglycolic acid sutures
30. Recent developments in biodegradable synthetic polymers10.1016/S1387-2656(06)12009-8 ↗
31. Polyglycolic acid-induced inflammation: Role of hydrolysis and resulting complement activation10.1089/ten.2006.12.301 ↗
32. Tissue response to polyglycolide, polydioxanone, polylevolactide, and metallic pins in cancellous bone: An experimental study on rabbits10.1002/jor.20191 ↗
33. Large-pore pds mesh compared to small-pore pg mesh10.3109/08941931003739741 ↗
34. Biomedical applications of biodegradable polymers10.1002/polb.22259 ↗
35. A 5-year in vitro and in vivo study of the biodegradation of polylactide plates10.1016/S0278-2391(98)90461-X ↗
36. Long-term toxicity of holmium-loaded poly(l-lactic acid) microspheres in rats10.1016/j.biomaterials.2007.07.012 ↗
37. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded plla or plga microspheres for the systemic targeting of human prostate tumors10.1007/s00280-007-0557-x ↗
38. Microencapsulation of puerarin nanoparticles by poly(L-lactide) in a supercritical CO2 process10.1016/j.actbio.2009.04.032 ↗
39. Preparation of biodegradable liquid core plla microcapsules and hollow plla microcapsules using microfluidics10.1002/mabi.200900404 ↗
40. Synthetic biodegradable polymers as orthopedic devices10.1016/S0142-9612(00)00101-0 ↗
41. Vicryl (polyglactin 910) synthetic absorbable sutures10.1016/0002-9610(74)90228-1 ↗
42. Evaluation of a diphtheria and tetanus plga microencapsulated vaccine formulation without stabilizers10.2174/156720109788680886 ↗
43. Stabilization of tetanus toxoid encapsulated in PLGA microspheres10.1021/mp800027f ↗
44. Influence of surface charge of PLGA particles of recombinant hepatitis b surface antigen in enhancing systemic and mucosal immune responses10.1016/j.ijpharm.2009.06.006 ↗
45. Particle size influences the immune response produced by hepatitis b vaccine formulated in inhalable particles10.1007/s11095-010-0094-x ↗
46. Evaluation of in vivo—In vitro release of dexamethasone from PLGA microspheres10.1016/j.jconrel.2008.01.004 ↗
47. A biodegradable drug delivery system for the treatment of postoperative inflammation10.1016/j.ijpharm.2007.10.054 ↗
48. Anti-tumor effects of anti-VEGF sirna encapsulated with plga microspheres in mice10.1016/j.jconrel.2007.11.017 ↗
49. Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted sirna and DNA vaccine to antigen-presenting cells10.1038/mt.2008.206 ↗
50. Polymeric nanoparticles for sirna delivery and gene silencing10.1016/j.ijpharm.2008.09.039 ↗
51. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres10.1023/A:1007582911958 ↗
52. Acidic microclimate ph distribution in plga microspheres monitored by confocal laser scanning microscopy10.1007/s11095-008-9594-3 ↗
53. An anisotropic nanofiber/microsphere composite with controlled release of biomolecules for fibrous tissue engineering10.1016/j.biomaterials.2010.01.098 ↗
54. Clinical evaluation of the capronor contraceptive implant: Preliminary report10.1016/S0002-9378(89)80015-8 ↗
55. Development and evaluation of novel biodegradable microspheres based on poly(D,L-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: In vitro and in vivo studies10.1016/j.jconrel.2007.01.008 ↗
56. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems10.1016/j.ymeth.2005.11.003 ↗
57. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics10.1002/jbm.820190806 ↗
58. Polyketal nanoparticles: A new ph-sensitive biodegradable drug delivery vehicle10.1021/bc050176w ↗
59. Polyketal microparticles: A new delivery vehicle for superoxide dismutase10.1021/bc060259s ↗
60. Lee, S., Yang, S.C., Kao, C.Y., Pierce, R.H., and Murthy, N. (2009). Solid polymeric microparticles enhance the delivery of sirna to macrophages in vivo. Nucleic Acids Res., 37.10.1093/nar/gkp758 ↗
61. Cross-linked microparticles as carriers for the delivery of plasmid DNA for vaccine development10.1021/bc034159n ↗
62. A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels10.1073/pnas.0930644100 ↗
63. Acid-degradable particles for protein-based vaccines: Enhanced survival rate for tumor-challenged mice using ovalbumin model10.1021/bc049956f ↗
64. Polyketal copolymers: A new acid-sensitive delivery vehicle for treating acute inflammatory diseases10.1021/bc700442g ↗
65. The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid)10.1016/j.biomaterials.2008.10.034 ↗
66. The delivery of superoxide dismutase encapsulated in polyketal microparticles to rat myocardium and protection from myocardial ischemia-reperfusion injury10.1016/j.biomaterials.2009.10.045 ↗
67. The in vivo and in vitro degradation behavior of poly(trimethylene carbonate)10.1016/j.biomaterials.2005.09.017 ↗
68. In vivo behavior of poly(1,3-trimethylene carbonate) and copolymers of 1,3-trimethylene carbonate with D,L-lactide or epsilon-caprolactone: Degradation and tissue response10.1002/jbm.a.10121 ↗
69. Loading and release of ibuprofen in multi- and monofilament surgical sutures10.1002/mabi.200600084 ↗
70. pH-responsive biodegradable micelles based on acid-labile polycarbonate hydrophobe: Synthesis and triggered drug release10.1021/bm900074d ↗
71. Ph-sensitive degradable polymersomes for triggered release of anticancer drugs: A comparative study with micelles10.1016/j.jconrel.2009.09.023 ↗
72. Hydrogen bonding-enhanced micelle assemblies for drug delivery10.1016/j.biomaterials.2010.07.018 ↗
73. Biocompatible and biodegradable poly(trimethylene carbonate)-b-poly(l-glutamic acid) polymersomes: Size control and stability10.1021/la902786t ↗
74. A simple method to achieve high doxorubicin loading in biodegradable polymersomes10.1016/j.jconrel.2010.07.123 ↗
75. A rapidly resorbable hemostatic biomaterial based on dihydroxyacetone10.1002/jbm.a.32586 ↗
76. Evaluation of a series of tyrosine-derived polycarbonates as degradable biomaterials10.1002/jbm.820280811 ↗
77. Tyrosine derived polycarbonate membrane is useful for guided bone regeneration in rabbit mandibular defects10.1007/s10856-005-2613-6 ↗
78. Tyrosine-derived polycarbonate membrane in treating mandibular bone defects. An experimental study10.1098/rsif.2006.0119 ↗
79. Cellular response to phase-separated blends of tyrosine-derived polycarbonates10.1002/jbm.a.30527 ↗
80. Osteogenic differentiation of human mesenchymal stem cells on poly(ethylene glycol)-variant biomaterials10.1002/jbm.a.32310 ↗
81. Interplay of anionic charge, poly(ethylene glycol), and iodinated tyrosine incorporation within tyrosine-derived polycarbonates: Effects on vascular smooth muscle cell adhesion, proliferation, and motility10.1002/jbm.a.32544 ↗
82. Electrospun mat of tyrosine-derived polycarbonate fibers for potential use as tissue scaffolding material10.1163/156856206778365988 ↗
83. Angiogenic competency of biodegradable hydrogels fabricated from polyethylene glycol-crosslinked tyrosine-derived polycarbonates10.22203/eCM.v015a06 ↗
84. Polymer-xerogel composites for controlled release wound dressings10.1016/j.biomaterials.2010.04.065 ↗
85. Biodegradable microspheres for vitreoretinal drug delivery10.1016/S0169-409X(01)00200-9 ↗
86. Anterior chamber migration of dexametasone intravitreal implant (ozurdex(r))10.1007/s00417-011-1802-x ↗
87. Advances in ophthalmic drug delivery10.4155/tde.14.75 ↗
88. Intraocular implants for extended drug delivery: Therapeutic applications10.1016/j.addr.2006.07.026 ↗
89. Polymers for drug delivery systems10.1146/annurev-chembioeng-073009-100847 ↗
90. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases10.1002/jps.21987 ↗
91. Long-term, controlled release of the hiv microbicide tmc120 from silicone elastomer vaginal rings10.1093/jac/dki326 ↗
92. Effect of supersaturation and crystallization phenomena on the release properties of a controlled release device based on eva copolymer10.1016/S0168-3659(02)00139-6 ↗
93. Ni3S2/Ni-P bilayer coated on polyimide as a Pt- and TCO-free flexible counter electrode for dye-sensitized solar cells10.1021/am405384c ↗
94. Poly(methyl methacrylate) particulate carriers in drug delivery10.3109/02652048.2011.651500 ↗
95. Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr10.1002/jps.10075 ↗
96. Drug delivery options for the treatment of ocular inflammation10.3109/08820538.2010.518522 ↗
97. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema10.1001/archopht.125.3.309 ↗
98. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or irvine-gass syndrome10.1016/j.ajo.2008.12.033 ↗
99. Wandering ozurdex((r)) implant10.1007/s12348-011-0042-x ↗
100. A comparison between the fluocinolone acetonide (retisert) and dexamethasone (ozurdex) intravitreal implants in uveitis10.1089/jop.2012.0180 ↗